These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36736917)

  • 21. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.
    van Velthoven R; Aoun F; Marcelis Q; Albisinni S; Zanaty M; Lemort M; Peltier A; Limani K
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):79-83. PubMed ID: 26597660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes.
    Feijoo ER; Sivaraman A; Barret E; Sanchez-Salas R; Galiano M; Rozet F; Prapotnich D; Cathala N; Mombet A; Cathelineau X
    Eur Urol; 2016 Feb; 69(2):214-20. PubMed ID: 26164416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.
    Ganzer R; Fritsche HM; Brandtner A; Bründl J; Koch D; Wieland WF; Blana A
    BJU Int; 2013 Aug; 112(3):322-9. PubMed ID: 23356910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The primary treatment of prostate cancer with high-intensity focused ultrasound: A systematic review and meta-analysis.
    He Y; Tan P; He M; Hu L; Ai J; Yang L; Wei Q
    Medicine (Baltimore); 2020 Oct; 99(41):e22610. PubMed ID: 33031318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-intensity focused ultrasound for prostate cancer: a systematic review.
    Lukka H; Waldron T; Chin J; Mayhew L; Warde P; Winquist E; Rodrigues G; Shayegan B;
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):117-27. PubMed ID: 20932728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
    J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [High-intensity focussed ultrasound in low-risk prostate cancer - oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre].
    Baumunk D; Andersen C; Heile U; Ebbing J; Cash H; Porsch M; Liehr UB; Janitzky A; Wendler JJ; Schindele D; Blaschke S; Miller K; Schostak M
    Aktuelle Urol; 2013 Jul; 44(4):285-92. PubMed ID: 23888408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
    Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
    Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
    Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
    Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
    BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial.
    Westhoff N; Ernst R; Kowalewski KF; Derigs F; Neuberger M; Nörenberg D; Popovic ZV; Ritter M; Stephan Michel M; von Hardenberg J
    Eur Urol Focus; 2023 Mar; 9(2):283-290. PubMed ID: 36344395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
    PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
    von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
    Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry.
    Lovegrove CE; Peters M; Guillaumier S; Arya M; Afzal N; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Virdi J; Winkler M; Emberton M; Ahmed HU; Shah TT; Minhas S
    BJU Int; 2020 Jun; 125(6):853-860. PubMed ID: 31971335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound.
    Holtzman AL; Hoppe BS; Letter HP; Bryant C; Nichols RC; Henderson RH; Mendenhall WM; Morris CG; Williams CR; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):465-471. PubMed ID: 26883560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
    Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
    Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.